FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus

FDA has approved Hovilpri (pritelivir) for immunocompromised adults with herpes simplex virus lesions that have not responded to specified antiviral therapies. FDA reports that all lesions healed by 28 days in 63% of Hovilpri recipients versus 34% receiving other treatments in the randomized trial.

Why it matters: FDA's account describes lesion healing as the primary endpoint and investigator-selected treatments as the comparator in this trial population.